Stage
Acquired Unit | AcquiredValuation
$0000About Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program
Nimbus Therapeutics, formerly Nimbus Discovery, harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company's focus on metabolic diseases, cancer and immune-inflammatory disorders is driven by its selection of well validated targets that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry. Using its unique approach and technological capabilities, Nimbus is rapidly progressing highly selective and potent small molecules through discovery and development. The company's advanced programs include ACC, IRAK4, and Tyk2. Nimbus is headquartered in Cambridge, Massachusetts (USA).
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Headquarter Location
25 First Street Suite 404
Cambridge, Massachusetts, 02141,
United States
857-999-2009
Expert Collections containing Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program is included in 1 Expert Collection, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Where is Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's headquarters?
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's headquarters is located at 25 First Street, Cambridge.
What is Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest funding round?
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest funding round is Acquired Unit.
Who are the investors of Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program?
Investors of Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program include Gilead Sciences.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.